The total return over the past 12 months is -16.59% vs. +16.94% for the S&P 500. So far it's up -27.50% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (16.59%) | (53.19%) | (55.06%) | N/A | N/A | N/A |
| Total Return CAGR | (16.59%) | (53.19%) | (55.06%) | N/A | N/A | N/A |
| Revenue CAGR | (51.65%) | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
X4 Pharmaceuticals, Inc. (XFOR)
| Year | Start price | End price | XFOR Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $4.00 | $2.90 | (27.50%) | +14.51% | (42.01%) |
| 2025 | $22.01 | $4.00 | (81.83%) | +17.72% | (99.55%) |
| 2024 | $25.16 | $22.01 | (12.52%) | +24.89% | (37.41%) |
| 2023 | $29.79 | $25.16 | (15.54%) | +26.19% | (41.73%) |
| 2022 | $68.70 | $29.79 | (56.64%) | (18.17%) | (38.47%) |
| 2021 | $192.90 | $68.70 | (64.39%) | +28.74% | (93.13%) |
| 2020 | $321.00 | $192.90 | (39.91%) | +18.37% | (58.28%) |
| 2019 | $417.60 | $321.00 | (23.13%) | +31.22% | (54.35%) |
| 2018 | $2,296.80 | $417.60 | (81.82%) | (4.56%) | (77.26%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
